VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Saturday morning. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $2.50 price objective on shares of VolitionRx in a report on Wednesday, March 27th.

VolitionRx Trading Up 1.4 %

Shares of VNRX traded up $0.01 during trading hours on Friday, reaching $0.89. 108,909 shares of the company’s stock traded hands, compared to its average volume of 320,236. VolitionRx has a 12 month low of $0.55 and a 12 month high of $2.09. The stock has a market cap of $73.12 million, a PE ratio of -1.75 and a beta of 1.26. The firm’s 50 day simple moving average is $0.83 and its 200-day simple moving average is $0.85.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. As a group, analysts expect that VolitionRx will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.